#trialnet search results

Today is a very, very happy day for this T1D father! Thank you @T1D_TrialNet If you have a kid, and anyone in your extended family has type 1 diabetes, please participate in #trialnet

🔥 Real-world medical trials are going Web3. #TrialNet now syncs wallet-auth patient consents, oracle-fed treatment protocols & DAO-rated outcome trails into onchain contracts. Not eForms — it’s programmable #DeSci with sovereign participation rails. 🧬📜 #RWA #DigitalIdentity

🧠 Real-world research is entering programmable rails. #TrialNet just deployed clinical trial coordination using wallet-auth patient flow, Git-verified treatment logs & DAO-synced evidence scoring. Not pharma portals — it’s sovereign discovery logic for public health. 🏥📜 #DeSci

We hope you enjoyed the exciting research presented at #ADA2025! Be sure to check out our #TrialNet presentations. Recorded sessions will remain available on the virtual platform through [DATE]. To learn more about #TrialNet visit us at trialnet.org.

We’re wrapping up #ADA2025 with “Celebrating NIDDK's 75th Anniversary—Clinical, Translational & Basic Advances, Current Research Priorities & Future Direction” where #TrialNet investigator Jeffrey Krischer @USFHealth will present “Today's Reality of Achieving Type 1 Prevention”

This afternoon at #ADA2025 Jason Gaglia @JoslinDiabetes presents #TrialNet research poster 726-P “Two-Year Follow-up of AVT001 Dendritic Cell Therapy for Type 1 Diabetes—Continued Off-Therapy Functional Effects and Characterization of Responders”

You won’t want to miss this afternoon’s #ADA2025 Poster Session where Heba Ismail @IUMedSchool will present #TrialNet research poster 1525-P “Genetic Ancestry and Progression through Type 1 Diabetes (T1D) Stages”

Start your day off with #ADA2025 Symposium “Continuous Ketone Monitoring—Innovations and clinical Applications” where #TrialNet researcher Jennifer Sherr @YaleIMed will present “Ketone Sensor Performance Criteria and Current Study Data”

Be sure to stop by #TrialNet booth #1048 in the #ADA2025 Exhibitor’s Hall for more information on #TrialNet #T1Dresearch and how to #screen4T1D @AmDiabetesAssn

Be sure to stop by today’s #ADA2025 Late Breaking Poster Session where #TrialNet investigator Alice Carr will present 1962-P “Baseline Insulin Secretion Determines the Response to Abatacept in Stage 1 T1D”

Plan to join today’s #ADA2025 Discussion on Diabetes in Youth—D-Tech and DEB—The Spectrum of Disordered Eating Behaviors in Children, Adolescents & Young Adults Using Diabetes Devices” led by #TrialNet investigator @Heba_T1D @IUMedSchool

Start day 3 at #ADA2025 with “Advances and Trends in Diabetes Technology” where #TrialNet investigator Andrea Steck @CUDiabetes will present “The Role of CGM in Staging Early T1D”

It’s day 3 at #ADA2025! Plan to attend this morning’s Symposium “Advances and Trends in Diabetes Technology” with #TrialNet investigator Andrea Steck. Then head over to “Discussion on Diabetes in Youth and Disordered Eating Behaviors” led by @Heba_T1D

Discover “What’s New with Interpretation of CGM Metrics and Relationship to A1C, eA1C and GMI?” where #TrialNet investigator Eslam Montaser @IUMedSchool will present “Evaluating the Impact of T1D Interventions on A1C and GMI across Glycemic Categories” #ADA2025

Don’t miss @Heba_T1D @IUMedSchool presenting #TrialNet research poster 1524-P “The Progression of 2-Hour Glucose (2hGLU) to Impaired Glucose Tolerance (IGT) and Its Reversion in Antibody-Positive (Ab+) Individuals?” at today’s #ADA2025 General Poster Session

Today at #ADA2025 Jason Gaglia @JoslinDiabetes presents #TrialNet research poster 726-P “Two-Year Follow-up of AVT001 Dendritic Cell Therapy for Type 1 Diabetes—Continued Off-Therapy Functional Effects and Characterization of Responders”

Today at #ADA2025 @Heba_T1D @IUMedSchool presents #TrialNet research poster 1523-P “Risk profiles and characteristics of individuals with single autoantibody (SAB) reversion in relatives at risk for Type 1 Diabetes (T1D)”

#TrialNet investigator @BrandonNathanMD presents poster 1510-P “An Insulin Secretion Independent Fraction of Glucose Obscures Associations of Age and BMI with Glucose in Autoantibody-Positive (Ab+) Individuals” today at #ADA2025

Check out #TrialNet investigator Alfonso Galderisi @YaleIMed presenting Poster 719-P “Oral Disposition Index (oDI) as an Outcome Measure in Type 1 Diabetes (T1D) Clinical Trials: Evidence from Stage 1 and Stage 2 T1D trials” at today’s #ADA2025 General Poster Session

Check out @BrandonNathanMD presenting #TrialNet research poster 705-P “Enhanced Detection of Efficacy in T1D Prevention Trials by Using Glucose Fractions” at today’s #ADA2025 General Poster Session

Delighted to announce the launch of #TrialNet's JAKPOT T1D study, testing #abrocitinib & #ritlecitinib in recent-onset Stage 3 #T1D. tinyurl.com/JAKPOTTID. Good to finally be at the starting line after 3 yrs of planning! @T1D_TrialNet @pfizer @IUSweetTweets

Check out @BrandonNathanMD presenting #TrialNet research poster 705-P “Enhanced Detection of Efficacy in T1D Prevention Trials by Using Glucose Fractions” at today’s #ADA2025 General Poster Session

Start your day off with #ADA2025 Symposium “Continuous Ketone Monitoring—Innovations and clinical Applications” where #TrialNet researcher Jennifer Sherr @YaleIMed will present “Ketone Sensor Performance Criteria and Current Study Data”

🧠 Real-world research is entering programmable rails. #TrialNet just deployed clinical trial coordination using wallet-auth patient flow, Git-verified treatment logs & DAO-synced evidence scoring. Not pharma portals — it’s sovereign discovery logic for public health. 🏥📜 #DeSci

🔥 Real-world medical trials are going Web3. #TrialNet now syncs wallet-auth patient consents, oracle-fed treatment protocols & DAO-rated outcome trails into onchain contracts. Not eForms — it’s programmable #DeSci with sovereign participation rails. 🧬📜 #RWA #DigitalIdentity

Key slide for $PRVB #TrialNet study news $LLY $MGNX

Today we got our #trialnet results back for my eldest. So far, no antibody markers for #T1D! Thanks to all the researchers doing great work to help progress with prevention, treatments and hopefully a cure for #diabetes

Don’t miss #TrialNet investigator @BrandonNathanMD at today’s #ADA2025 General Poster Session where he’ll present “Quality of Life and Diabetes Distress among Children & Youth with T1D & Their Parents in Kampala, Uganda—Cross-Sectional Survey” (691-P)

Changes in insulin secretion & clearance predict progression in stage 2 type 1 diabetes & response to teplizumab. Oral-minimal model identifies disease heterogeneity in stage 2 #T1D @YaleMed #TrialNet @BreakthroughT1D @UMNews @IndianaUniv #T1Dprevention link.springer.com/article/10.100… 🔓

We’re wrapping up #ADA2025 with “Celebrating NIDDK's 75th Anniversary—Clinical, Translational & Basic Advances, Current Research Priorities & Future Direction” where #TrialNet investigator Jeffrey Krischer @USFHealth will present “Today's Reality of Achieving Type 1 Prevention”

Today is a very, very happy day for this T1D father! Thank you @T1D_TrialNet If you have a kid, and anyone in your extended family has type 1 diabetes, please participate in #trialnet

Today’s #ADA2025 session “Diabetes in Children--Decoding Disease & Transforming Care” features #TrialNet research presented by Alfonso Galderisi “Lower Incretin Effect & Reduced GIP Characterize Metabolic Phenotype of People w/ Multiple Islet AAbs & Normal Glucose Tolerance”

@LindaDiMeglio presented #TrialNet which is an international network of researchers, academic institutions, physicians, scientists, and healthcare teams at the forefront of type 1 diabetes research.

At today’s #ADA2025 General Poster Session #TrialNet investigator Holly O’Donnell @CUDiabetes provides insight into “Understanding Participant Decision Making for Enrolling in an Intervention Trial to Delay Stage 3 T1D” with poster 712-P

More than a quarter million people have learned their risk of developing type 1 diabetes (T1D) through #TrialNet screening. TrialNet and Breakthrough T1D announced the research milestone as part of #NationalDiabetesMonth. Contact [email protected] to learn more.

Be sure to stop by today’s #ADA2025 Late Breaking Poster Session where #TrialNet investigator Alice Carr will present 1962-P “Baseline Insulin Secretion Determines the Response to Abatacept in Stage 1 T1D”

Start day 3 at #ADA2025 with “Advances and Trends in Diabetes Technology” where #TrialNet investigator Andrea Steck @CUDiabetes will present “The Role of CGM in Staging Early T1D”

Check out #TrialNet investigator Alfonso Galderisi @YaleIMed presenting Poster 719-P “Oral Disposition Index (oDI) as an Outcome Measure in Type 1 Diabetes (T1D) Clinical Trials: Evidence from Stage 1 and Stage 2 T1D trials” at today’s #ADA2025 General Poster Session

Multiple stages of #type1diabetes exist. Identifying prediabetes symptoms can prevent complications. Our center participates in TrialNet - a study aimed at reducing DKA risk at diagnosis. Learn more here: bit.ly/4f4K4Xs #diabetesresearch #TrialNet #DKA #UChiMed

Today at #ADA2025 @Heba_T1D @IUMedSchool presents #TrialNet research poster 1523-P “Risk profiles and characteristics of individuals with single autoantibody (SAB) reversion in relatives at risk for Type 1 Diabetes (T1D)”